Shares of Moderna slid 3.58% to $125.01 at 17:17 EST on Tuesday, following last session’s downward trend. NASDAQ Composite is rising 1.53% to $13,197.18, after two successive sessions in a row of losses. This seems, up to now, an all-around positive trend exchanging session today.
Moderna’s last close was $129.65, 42.79% below its 52-week high of $178.50.
News about Moderna today
Moderna aiding California inquiry into allergic reactions. According to today’s article on Bloomberg Quint, "Of those, 964,900 doses already have been distributed to about 1,700 vaccination sites in 37 states, Moderna said. ", "This investigation is still ongoing and Moderna is working closely" with the U.S. Food and Drug Administration and CDC "to understand the clinical cases and whether the broad pause in use of the lot is warranted," the company said in a statement."
Moderna’s sales growth is 1986.4% for the current quarter and 19117.5% for the next. The company’s growth estimates for the current quarter and the next is 18.9% and 660%, respectively.
Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.
Moderna’s last day, last week, and last month’s average volatility was a negative 0.05%, a positive 2.87%, and a negative 0.64%, respectively.
Moderna’s last day, last week, and last month’s high and low average amplitude percentage was 5.30%, 6.39%, and 8.17%, respectively.
Moderna’s Stock Yearly Top and Bottom Value
Moderna’s stock is valued at $125.01 at 17:17 EST, way below its 52-week high of $178.50 and way above its 52-week low of $17.91.
Moderna’s Moving Average
Moderna’s worth is below its 50-day moving average of $133.89 and way higher than its 200-day moving average of $88.29.